Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

### Burkitt Lymphoma

Note: All recommendations are Category 2A unless otherwise indicated.

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| **CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab**       | **Day 1**: Cyclophosphamide 187.5–200mg/m² IV + doxorubicin 12.5mg/m² IV + etoposide 60mg/m² IV  
**Day 1**: Rituximab 375mg/m² IV just before CDE regimen.  
Repeat cycle every 4 weeks for a maximum of 6 cycles. |
| **CODOX-M/IVAC (modified)** (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine)** | **Day 1**: Cyclophosphamide 800mg/m² IV, followed by  
**Day 2–5**: Cyclophosphamide 200mg/m² IV  
**Day 1**: Doxorubicin 40mg/m² IV  
**Days 1 and 8: Cycle 1**: Vincristine 1.5mg/m² IV; **Cycle 2**: Days 1, 8, and 15.  
**Day 1**: MTX 1,200mg/m² IV over 1 hour, followed by 240mg/m²/hour over 23 hours.  
**Days 1 and 3**: Cytarabine 70mg intrathecally.  
**Day 1**: Rituximab 375mg/m² IV.  
**Day 15**: MTX 12mg intrathecally.  
**Alternate with:**  
**Days 1–5**: Ifosfamide 1,500mg/m² IV + etoposide 60mg/m² IV  
**Days 1 and 2**: Cytarabine 2,000mg/m² IV every 12 hours for 4 doses  
**Day 1**: Rituximab 375mg/m² IV  
**Day 15**: MTX 12mg intrathecally. |
| **Dose-adjusted EPOCH** (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + rituximab** | **Days 1–4**: Etoposide 50mg/m² IV + prednisone 60mg/m² orally + vincristine 0.4mg/m² IV + doxorubicin 10mg/m² IV  
**Day 1**: Rituximab 375mg/m² IV  
**Day 5**: Prednisone 60mg/m² orally  
**Day 5**: Cycle 1: Cyclophosphamide 375mg/m³ IV if CD4 cells ≥100/mm³ OR 187mg/m² IV if CD4 cells <100/mm³.  
**Cyclophosphamide dose-adjustment (after Cycle 1)**: If nadir ANC >500/mcL, then increase by 187mg above previous cycle. If nadir ANC <500/mcL, or platelets <25,000/mcL, then decrease by 187mg below previous cycle.  
Repeat cycle every 3 weeks. |
| **HyperCVAD** (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine)** | **Cycles 1, 3, and 7—HyperCVAD**  
**Days 1–3**: Cyclophosphamide 300mg/m² IV every 12 hours for 6 doses, plus mesna 600mg/m² continuous IV  
**Days 4 and 11**: Vincristine 2mg IV  
**Day 4**: Doxorubicin 50mg/m² IV.  
**Days 1–4 and Days 11–14**: Dexamethasone 40mg daily.  
**Cycles 2, 4, 6, 8—High-dose MTX and Cytarabine**  
**Day 1**: MTX 1g/m² IV over 24 hours  
**Days 2 and 3**: Cytarabine 3g/m² IV every 12 hours for 4 doses.  
Repeat every 3 weeks for 8 cycles. |
**NON-HODGKIN LYMPHOMA TREATMENT REGIMENS:**
AIDS-Related B-Cell Lymphomas (Part 2 of 3)

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + rituximab</strong>&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td><strong>Days 1–4:</strong> Etoposide 50mg/m² IV + prednisone 60mg/m² orally + vincristine 0.4mg/m² IV + doxorubicin 10mg/m² IV <strong>Day 1:</strong> Rituximab 375mg/m² IV <strong>Day 5:</strong> Prednisone 60mg/m² orally <strong>Day 5:</strong> <strong>Cycle 1:</strong> Cyclophosphamide 375mg/m³ IV if CD4 cells ≥100/mm³ OR 187mg/m³ IV if CD4 cells &lt;100/mm³. <strong>Cyclophosphamide dose-adjustment (after Cycle 1):</strong> If nadir ANC &gt;500/mcL, then increase by 187mg above previous cycle. If nadir ANC &lt;500/mcL, or platelets &lt;25,000/mcL, then decrease by 187mg below previous cycle. Repeat cycle every 3 weeks.</td>
</tr>
<tr>
<td><strong>CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab</strong>&lt;sup&gt;2–4&lt;/sup&gt;</td>
<td><strong>Days 1–4:</strong> Cyclophosphamide 187.5–200mg/m² IV + doxorubicin 12.5mg/m² IV + etoposide 60mg/m² IV <strong>Day 1:</strong> Rituximab 375mg/m² IV just before CDE regimen. Repeat cycle every 4 weeks for a maximum of 6 cycles.</td>
</tr>
<tr>
<td><strong>CHOP + rituximab</strong>&lt;sup&gt;13–15c&lt;/sup&gt;</td>
<td><strong>Option 1—Modified CHOP</strong> <strong>Day 1:</strong> Cyclophosphamide 375mg/m² IV + doxorubicin 25mg/m² IV + vincristine 1.4mg/m² IV (2mg maximum) <strong>Days 1–5:</strong> Prednisone 100mg orally <strong>Day 1:</strong> Rituximab 375mg/m² IV. Repeat cycle every 3 weeks for at least 4 cycles, or for 2 cycles after complete response. <strong>Option 2—Standard-dose CHOP</strong> <strong>Day 1:</strong> Cyclophosphamide 750mg/m² IV + doxorubicin 50mg/m² IV + vincristine 1.4mg/m² IV (2mg maximum) <strong>Days 1–5:</strong> Prednisone 100mg orally <strong>Day 1:</strong> Rituximab 375mg/m² IV. Repeat cycle every 3 weeks for at least 4 cycles, or for 2 cycles after complete response.</td>
</tr>
<tr>
<td><strong>Plasmablastic Lymphoma</strong>&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td><strong>CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine)</strong>&lt;sup&gt;5–7&lt;/sup&gt; <strong>Day 1:</strong> Cyclophosphamide 800mg/m² IV, followed by <strong>Days 2–5:</strong> Cyclophosphamide 200mg/m² IV <strong>Day 1:</strong> Doxorubicin 40mg/m² IV <strong>Days 1 and 8: Cycle 1:</strong> Vincristine 1.5mg/m² IV; <strong>Cycle 2:</strong> Days 1, 8, and 15. <strong>Day 1:</strong> MTX 1,200mg/m² IV over 1 hour, followed by 240mg/m²/hour over 23 hours. <strong>Days 1 and 3:</strong> Cytarabine 70mg intrathecally. <strong>Day 1:</strong> Rituximab 375mg/m² IV. <strong>Day 15:</strong> MTX 12mg intrathecally. <strong>Alternate with:</strong> <strong>Days 1–5:</strong> Ifosfamide 1,500mg/m² IV + etoposide 60mg/m² IV <strong>Days 1 and 2:</strong> Cytarabine 2,000mg/m² IV every 12 hours for 4 doses <strong>Day 1:</strong> Rituximab 375mg/m² IV <strong>Day 15:</strong> MTX 12mg intrathecally.</td>
</tr>
<tr>
<td><strong>Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + rituximab</strong>&lt;sup&gt;8–10a&lt;/sup&gt;</td>
<td><strong>Days 1–4:</strong> Etoposide 50mg/m² IV + prednisone 60mg/m² orally + vincristine 0.4mg/m² IV + doxorubicin 10mg/m² IV <strong>Day 1:</strong> Rituximab 375mg/m² IV <strong>Day 5:</strong> Prednisone 60mg/m² orally <strong>Day 5:</strong> <strong>Cycle 1:</strong> Cyclophosphamide 375mg/m² IV if CD4 cells ≥100/mm³ OR 187mg/m² IV if CD4 cells &lt;100/mm³. <strong>Cyclophosphamide dose-adjustment (after Cycle 1):</strong> If nadir ANC &gt;500/mcL, then increase by 187mg above previous cycle. If nadir ANC &lt;500/mcL, or platelets &lt;25,000/mcL, then decrease by 187mg below previous cycle. Repeat cycle every 3 weeks.</td>
</tr>
</tbody>
</table>

*continued*
### Primary CNS Lymphoma

- Initiate highly active antiretroviral therapy (HAART)
- Even with poorly controlled HIV and/or marginal performance status, consider high-dose methotrexate.
- Consider RT alone for palliation of patients who are not candidates for systemic therapy.
- For select patients with good performance status on HAART, see NCCN Guidelines for CNS cancers.
- Best supportive care.

#### References


### Plasmablastic Lymphoma

#### REGIMEN

HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine)\(^{11-13}\)

#### DOSING

**Cycles 1, 3, 5, and 7—HyperCVAD**

| Days 1–3: | Cyclophosphamide 300mg/m\(^2\) IV every 12 hours for 6 doses, plus mesna 600mg/m\(^2\) continuous IV |
| Days 4 and 11: | Vincristine 2mg IV |
| Day 4: | Doxorubicin 50mg/m\(^2\) IV. |
| Days 1–4 and Days 11–14: | Dexamethasone 40mg daily. |

**Cycles 2, 4, 6, 8—High-dose MTX and Cytarabine**

| Day 1: | MTX 1g/m\(^2\) IV over 24 hours |
| Days 2 and 3: | Cytarabine 3g/m\(^2\) IV every 12 hours for 4 doses. Repeat every 3 weeks for 8 cycles. |